Confronting the Crisis: New Tools to Meet the Challenge of Multidrug-Resistant Bacteria
Pre-Activity Survey

Pre-Test

Question Title

1. All of the following were identified by the World Health Organization as critical priority pathogens except:

Methicillin-resistant S. aureus

Carbapenem-resistant P. aeruginosa

Carbapenem-resistant A. baumannii

Carbapenem-resistant, ESBL-producing Enterobacteriaceae

Question Title

2. Newer beta-lactam/beta-lactamase inhibitor agents (i.e., ceftolozane-tazobactam, ceftazidime-avibactam) exhibit activity against all of the following resistant organisms except:

ESBL-producing K. pneumoniae

Fluoroquinolone-resistant E. coli

Metallo-beta-lactamase-producing K. pneumoniae

Multidrug-resistant P. aeruginosa

Question Title

3. TEM-1, TEM-2, and SHV-1 all belong to the beta-lactamase ambler class:

A

B

C

D

Question Title

4. Which of the following is the most appropriate initial antimicrobial for a 72-year-old man with a complicated UTI caused by an ESBL-producing K. pneumoniae?

Moxifloxacin

Ceftazidime

Meropenem

Linezolid

Question Title

5. Which of the following agents in development exhibits the greatest in vitro activity against Acinetobacter baumannii?

Imipenem-relebactam

Cefiderocol

Meropenem-vaborbactam

Plazomicin

Question Title

6. Risk factors for infection caused by a multidrug-resistant Gram-negative organism include all of the following except:

High prevalence of institutional MDR bacteria

Prophylactic use of antimicrobials

Cystic fibrosis

No previous history of MDR infection